Showing results (51-60 of 215) with videos related to

Sort By:
Pageof 22
Cancers|December 23, 2023
Cytokine Modification of Adoptive Chimeric Antigen Receptor Immunotherapy for GlioblastomaKristen D Pawlowski, Joseph T Duffy, Stephen Gottschalk, et al.
Molecular Therapy. Methods & Clinical Development|March 20, 2018
Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of GliomaZhongzhen Yi, Brooke L Prinzing, Felicia Cao, et al.
Oncoimmunology|December 3, 2021
Unifying heterogeneous expression data to predict targets for CAR-T cell therapyPatrick Schreiner, Mireya Paulina Velasquez, Stephen Gottschalk, et al.
The Lancet. Oncology|October 2, 2013
Is cancer gene therapy an empty suit?Malcolm K Brenner, Stephen Gottschalk, Ann M Leen, et al.
Plos One|December 19, 2013
A vaccine that co-targets tumor cells and cancer associated fibroblasts results in enhanced antitumor activity by inducing antigen spreadingStephen Gottschalk, Feng Yu, Minjun Ji, et al.
Blood Advances|July 3, 2025
Age-Adjusted Dosing of Fludarabine for Lymphodepletion in CAR T-cell Therapy: A Clinical Trial Simulation StudyJohn C Panetta, Aimee C Talleur, Swati Naik, et al.
JCI Insight|November 5, 2020
MyD88/CD40 signaling retains CAR T cells in a less differentiated stateBrooke Prinzing, Patrick Schreiner, Matthew Bell, et al.
Cancer Discovery|August 13, 2017
Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor ModelsMelinda Mata, Claudia Gerken, Phuong Nguyen, et al.
Pediatric Blood & Cancer|October 16, 2018
Salvage regimens for pediatric patients with relapsed nasopharyngeal carcinomaChristopher DeRenzo, Catherine Lam, Carlos Rodriguez-Galindo, et al.
Cancer Gene Therapy|September 3, 2020
Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumoursKenneth Hsu, Shiloh Middlemiss, Federica Saletta, et al.
Pageof 22